GLP-1 drugs such as Ozempic, Wegovy and Zepbound have exploded in popularity for their ability to drive rapid weight loss. But emerging research suggests the pounds disappearing on the scale may not tell the whole story. Scientists recently found that people taking GLP-1 medications became less physically active after starting treatment, despite losing weight — a surprising finding that challenges the assumption that weight loss naturally leads to more movement.
Using real-world Fitbit data from hundreds of adults with obesity, researchers observed significant declines in both daily step counts and moderate-to-vigorous physical activity after participants began GLP-1 therapy. This trend raises concerns because these medications do not target fat alone. They also contribute to the loss of lean muscle mass, making regular movement and resistance training especially important for preserving strength, mobility and metabolic health.
For years, many people have been sold the idea that weight loss itself is the ultimate measure of health. But muscle is one of the body's most valuable assets, particularly as we age. It supports balance, insulin sensitivity, metabolic function and independence. The findings serve as an important reminder that health cannot be reduced to a number on the scale. Protecting muscle mass through strength-building activities and proper nutrition may be just as important as losing excess body fat in the first place.
SOURCE:
Neuroscience News, June 13, 2026